NKF K/DOQI GUIDELINES 2000
GUIDELINES FOR VASCULAR ACCESS
VIII. Biographical Sketches of the NKF-K/DOQI Vascular Access Work Group Members
The following are brief sketches that describe the professional training, experience, and principal business affiliations of the Work Group members. All Work Group members completed a disclosure statement certifying that any potential conflict of interest would not influence their judgment or actions concerning the NKF-DOQI.
Steve Schwab, MD (Work Group Chair), is Professor and Vice Chairman of Medicine and Co-Chief for the Division of Nephrology at the Duke University Medical Center; He also serves as Chief, Section of Hospital Medicine. Dr. Schwab serves on multiple editorial boards. Dr. Schwab is a member of the American Board of Internal Medicine Subspecialty Board for Nephrology and also serves on the American Society of Nephrologys Clinical Research Committee. He is the author of more than 100 articles and chapters dealing with issues in nephrology and end-stage renal disease. Dr. Schwab reported receiving grant funding from the NIH and Amgen Inc. He serves on medical advisory boards for Gambro, VascA Inc., and Amgen Inc.
Anatole Besarab, MD, FACP (Work Group Vice-Chair), is Chief, Section of Nephrology, West Virginia University School of Medicine. Dr. Besarab has been a practicing nephrologist for 25 years. In the past decade, his work in ESRD has focused on optimizing the management of anemia and detecting vascular access dysfunction prior to thrombosis. He has been a consultant to industry and has served on local and national committees. Dr. Besarab has published more than 100 articles, ranging from basic science to clinical practice, and his work has been presented at most of the national and international nephrology society meetings. He has been on the editorial board of several journals and has been active in many societies. His current research interests include evaluation of diagnostic tests to detect angioaccess dysfunction and developing algorithms which maximize hematopoietic response to recombinant human erythropoietin. Dr. Besarab reported affiliations with Amgen Inc. and Schein Pharmaceuticals.
Gerald Beathard, MD, PhD, FACP, is a member of Capital Nephrology Associates of Austin, Texas. He practices nephrology on a half time basis. His practice is primarily limited to Interventional Nephrology. He is also the Medical Director of U.S. Vascular Access Centers. Dr Beathard has been actively involved with the endovascular treatment of dialysis access dysfunction since 1987 and has extensive experience in these procedures. He is the Medical Director of Nephrology Vascular Laboratory at St. Davids Hospital in Austin, Texas. He has published articles dealing with all aspects of dialysis vascular access and has been involved in workshops dealing with this area for several years. Dr. Beathard has been active in the practice of nephrology for 32 years. He is on the Editorial Boards of several journals. He holds appointments to the faculty at LSU Medical School in Shreveport, Louisiana, the University of Texas Health Science Center in Houston, Texas and the University of Texas medical Branch, Galveston, Texas.
Deborah Brouwer, RN, CNN, is a nephrology nurse with 17 years of clinical experience in all forms of renal replacement therapies. She has worked as an acute and chronic dialysis staff nurse, nursing supervisor, staff education coordinator, CQI Coordinator and a Clinical Support Specialist. Currently she is the Education and Development Specialist for the Division of Nephrology and Hypertension at Allegheny General Hospital in Pittsburgh, PA. Ms. Brouwer has published on the topic of vascular access nursing care issues. She enjoys lecturing about nursing issues involving vascular access at professional meetings around the country. She is an active volunteer with the NKF on the Public Education Committee and serves as the Nursing editor of the Family Focus Newsletter. She is an active member of the local ANNA Three Rivers chapter.
Michael Levine, MD, is the Director of the Arteriovenous Hemodialysis Access Maintenance Program, Section of Interventional Nephrology, for Milwaukee Nephrologists, a private nephrology practice in Milwaukee, Wisconsin. A board certified nephrologist, for the last seven years Dr. Levines clinical practice has been dedicated to vascular access monitoring and percutaneous access salvage utilizing balloon angioplasty and mechanical thrombectomy. Dr. Levine oversees the care of the arteriovenous dialysis accesses for 400 hemodialysis patients, and in doing so, has performed approximately 700 percutaneous interventions on AV grafts and fistulae over the previous three years. His current areas of interest are the prevention of access thrombosis based on monthly intra-access flow measurements, developing strategies to increase the prevalence of native AV fistulae in the United States, percutaneous salvage of the failing to mature AV fistula, and methods, in addition to angiography, for accurately assessing the success of an intervention during the actual procedure. Dr. Levine is a member of the International Vascular Access Society, gives lectures on dialysis vascular access in the United States and abroad, and trained nephrologists from around the country in interventional techniques. While working on K/DOQI, Dr. Levine was a member of the Division of Nephrology and Hypertension at Beth Israel Medical Center in New York City.
Richard McCann, MD, FACS, is Professor of Surgery and Chief of the Vascular Surgery service at Duke University Medical Center in Durham, North Carolina. Dr. McCann trained in general and vascular surgery at Duke from 1974-1983 and was appointed to the faculty following his residency. He has been active in vascular surgery, vascular access surgery, and kidney transplantation for more than 10 years. He has published 91 articles in peer-reviewed journals dealing with vascular surgery and vascular access. Dr. McCann is a member of the American Society of Transplant Surgeons, the American Surgical Society, the Southern Surgical Association, the Southern Association for Vascular Surgery, and the Society for Vascular Surgery.
Richard Sherman, MD, is the Medical Director of ESRD Services and Professor of Medicine at the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School. He was Medical Director of Dialysis at Robert Wood Johnson University Hospital in New Brunswick, New Jersey for 18 years and at the Dialysis Clinics, Inc., North Brunswick, New Jersey for 5 years. He founded and edits the bimonthly journal Seminars in Dialysis. Dr. Sherman has published more than 100 articles and, in recent years, has had particular interest in improving the evaluation of vascular access for hemodialysis. He is a member of the speakers program for Amgen, Inc. and Ortho Biotech, Inc. and serves as a consultant to Aksys, Ltd. Dr. Sherman reported receiving grant funding from Baxter Healthcare and R & D Laboratories.
Scott Trerotola, MD, is the Director of Vascular and Interventional Radiology and Professor of Radiology at Indiana University School of Medicine. Dr. Trerotola has had an active interest in hemodialysis access for more than 10 years and has published over 100 articles in peer reviewed journals, many describing the role of interventional radiology in hemodialysis access. His current research centers on the role of mechanical thrombolysis and stents in hemodialysis access, and he is a strong advocate of the physical examination of access sites. Dr. Trerotola is active in several professional societies and is on the editorial board of four radiology journals. He holds four US patents and is the inventor of the Arrow-Trerotola Percutaneous Thrombolytic Device, widely used in the percutaneous treatment of thrombosed hemodialysis access grafts.
© 2001 National Kidney Foundation, Inc